METAvivor Lunch and Learn Series: Metastatic Breast Cancer Testing

METAvivor Research and Support

METAvivor Lunch and Learn Series: Testing

Wednesday, October 26, 2022 at1 pm EST/12 noon CST/10 am PST: Join us for a webinar featuring Rebecca Watters, PhD, MBA, Medical Science Liaison at Natera.Rebecca Watters will discuss circulating tumor DNA (ctDNA) tests (The SignateraTM Residual Disease Test) and tumor genomic profile tests (AlteraTM Comprehensive Genomic Profile), how they work, and why they are so important for informing care for people with metastatic breast cancer. You will leave this event knowing:<ul><li>The basics of ctDNA testing and tumor genomic profiling</li><li>More details about Natera’s SignateraTM </li><li>How you can work with your care team to integrate SignateraTM into your care plan</li></ul>Wednesday, November 2, 2022 at 1 pm EST/12 noon CST/10 am PST: Join us for a webinar featuring Rebecca Watters, PhD, MBA, Medical Science Liaison at Natera. Rebecca Watters will discuss circulating tumor DNA (ctDNA) tests (The SignateraTM Residual Disease Test) and tumor genomic profile tests (AlteraTM Comprehensive Genomic Profile), how they work, and why they are so important for informing care for people with metastatic breast cancer. You will leave this event knowing:<ul><li>The basics of ctDNA testing and tumor genomic profiling</li><li>More details about Natera’s AlteraTM </li><li>How you can work with your care team to integrate AlteraTM into your care plan</li></ul>More details about Natera’s AlteraTM How you can work with your care team to integrate AlteraTM into your care planW﻿ednesday, November 9, 2022 at 1 pm EST/12 noon CST/10 am PST: Join us for a webinar featuring Cliff Reid, PhDCliff will discuss METAvivor Early Access to Travera Rapid Therapy Guidance Testing - The fast track to selecting your next bridge therapy, through a cutting-edge new test. Through a special access partnership between METAvivor and Travera, Cliff will introduce a cutting-edge new testing technology developed at MIT. The Travera Rapid Therapy Guidance test provides uniquely individualized drug recommendations to help you make decisions about your next treatment or therapy. This unique assay doesn’t use genetics or genomics, it directly measures the effects of different drugs on YOUR actual cancer cells to predict therapeutic response for up to 20 different therapeutic options, allowing you to better select your next treatment or therapy in the most individualized way available today.*﻿Recordings will available on www.Metavivor.org on November 10th.

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

METAvivor Lunch and Learn Series: Metastatic Breast Cancer Testing

More events from METAvivor Research and Support

Discover more events from METAvivor Research and Support, from Health to other experiences you might love.

Still looking for the right event?

Explore all online events to browse and filter by date, category, and more.

METAvivor Lunch and Learn Series: Metastatic Breast Cancer Testing

More events from METAvivor Research and Support

Discover more events from METAvivor Research and Support, from Health to other experiences you might love.

More Health events

Browse more Health events with different dates, prices, and formats to find your next great experience.

Still looking for the right event?

Explore all online events to browse and filter by date, category, and more.